Table 3.

Results of network meta-analyses on treatment benefit and harm for comparisons between active agents and no active treatment, by surgery category

Intervention	Network odds ratio (95% CI)
	Any symptomatic venous thromboembolism				Major bleeding
	All surgeries	Orthopaedic surgeries	Non-orthopaedic surgeries		All surgeries	Orthopaedic surgeries	Non-orthopaedic surgeries
No of direct comparison (No of events/No of patients)	25 (235/30 230)	19 (193/28 293)	6 (42/1937)		55 (345/41 023)	42 (296/37 506)	13 (49/3517)
Low dose LMWH	0.33 (0.16 to 0.67)	0.53 (0.23 to 1.24)	0.10 (0.03 to 0.37)		2.04 (1.28 to 3.22)*	1.03 (0.47 to 2.26)	1.93 (0.78 to 4.82)
High dose LMWH	0.19 (0.07 to 0.54)	0.29 (0.09 to 0.91)	NA		3.07 (1.39 to 6.77)	2.03 (0.84 to 4.92)	1.90 (0.03 to 129.92)
Direct oral anticoagulants	0.17 (0.07 to 0.41)†	0.27 (0.10 to 0.71)‡	0.07 (0.01 to 0.60)§		2.01 (1.08 to 3.73)	1.25 (0.56 to 2.77)	1.86 (0.08 to 44.40)

LMWH= low molecular weight heparin; NA=not available.

^*Based on direct comparison.

^†Network odds ratio for direct oral anticoagulants versus low dose LMWH on symptomatic venous thromboembolism is 0.53 (95% confidence interval 0.32 to 0.89).

^‡Network odds ratio for direct oral anticoagulants versus low dose LMWH on symptomatic venous thromboembolism is 0.51 (0.31 to 0.85).

^§Network odds ratio for direct oral anticoagulants versus low dose LMWH on symptomatic venous thromboembolism is 0.64 (0.11 to 3.85).